Evidence map›Paper›PMID 30842805›Full record

ReviewWorld journal of stem cells2019

Rational use of mesenchymal stem cells in the treatment of autism spectrum disorders.

Qiang Liu, Mo-Xian Chen, Lin Sun, Chloe U Wallis, Jian-Song Zhou, Li-Juan Ao, Qi Li, Pak C Sham

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of stem cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Stem cell-based therapy for human diseases.Signal transduction and targeted therapy · 2022
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qiang LiuDepartment of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
Mo-Xian ChenSchool of Rehabilitation, Kunming Medical University, Kunming 650500, Yunnan Province, China.
Lin SunDepartment of Psychology, Weifang Medical University, Weifang 261053, Shandong Province, China.
Chloe U WallisMedical Sciences Division, University of Oxford, Oxford OX3 9DU, United Kingdom.
Jian-Song ZhouMental Health Institute of the Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China.
Li-Juan AoSchool of Rehabilitation, Kunming Medical University, Kunming 650500, Yunnan Province, China.
Qi LiDepartment of Psychiatry, the University of Hong Kong, Hong Kong, China. liqihku@gmail.com.
Pak C ShamDepartment of Psychiatry, the University of Hong Kong, Hong Kong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autism and autism spectrum disorders (ASD) refer to a range of conditions characterized by impaired social and communication skills and repetitive behaviors caused by different combinations of genetic and environmental influences. Although the pathophysiology underlying ASD is still unclear, recent evidence suggests that immune dysregulation and neuroinflammation play a role in the etiology of ASD. In particular, there is direct evidence supporting a role for maternal immune activation during prenatal life in neurodevelopmental conditions. Currently, the available options of behavioral therapies and pharmacological and supportive nutritional treatments in ASD are only symptomatic. Given the disturbing rise in the incidence of ASD, and the fact that there is no effective pharmacological therapy for ASD, there is an urgent need for new therapeutic options. Mesenchymal stem cells (MSCs) possess immunomodulatory properties that make them relevant to several diseases associated with inflammation and tissue damage. The paracrine regenerative mechanisms of MSCs are also suggested to be therapeutically beneficial for ASD. Thus the underlying pathology in ASD, including immune system dysregulation and inflammation, represent potential targets for MSC therapy. This review will focus on immune dysfunction in the pathogenesis of ASD and will further discuss the therapeutic potential for MSCs in mediating ASD-related immunological disorders.

Indexed as

Autism spectrum disordersCell therapyInflammationMajor histocompatibility complexMaternal immune activationMesenchymal stem cells

Identifiers

PMID30842805
PMCPMC6397804

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.